Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 7/20 | 0.35 |
| ▸ | MMP3 | P08254 | 7/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461235 | 0.93 | MMP1 (0.40) | DUTMMP1MMP3F2F10 | |
| SCHEMBL2463051 | 0.87 | F2 (0.43) | DUTMMP1MMP3FPR2F2 | |
| SCHEMBL4089316 | 0.87 | F2 (0.43) | DUTMMP1MMP3FPR2F2 | |
| SCHEMBL4089318 | 0.87 | F2 (0.43) | DUTMMP1MMP3FPR2F2 | |
| SCHEMBL4093297 | 0.81 | F2 (0.51) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL4093293 | 0.81 | F2 (0.51) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL2458572 | 0.80 | F2 (0.48) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL2458573 | 0.80 | F2 (0.48) | MMP1MMP3F2F10PRSS1 | |
| SCHEMBL21389263 | 0.78 | PIK3CD (0.44) | DUTBUB1NPC1RAB9A | |
| SCHEMBL26744185 | 0.78 | PIK3CD (0.44) | DUTBUB1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090149443-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149443-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPK1, MAPK4, BRIX1 | DUT 4471/4885MMP1 2463/4885MMP3 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.